Combined metformin and insulin treatment reverses metabolically impaired omental adipogenesis and accumulation of 4-hydroxynonenal in obese diabetic patients

Redox Biology

Volumn 12, Issue , 2017, Pages 483-490

  Jaganjac, Morana ^a   Almuraikhy, Shamma ^a,b   Al Khelaifi, Fatima ^a   Al Jaber, Mashael ^a   Bashah, Moataz ^c   Mazloum, Nayef A ^d   Zarkovic, Kamelija ^e   Zarkovic, Neven ^f   Waeg, Georg ^g   Kafienah, Wael ^b   Elrayess, Mohamed A ^a  

^a Anti Doping Lab Qatar ^*  (Qatar)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c HAMAD MEDICAL CORPORATION   (Qatar)

^d WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^e KBC Zagreb   (Croatia)

^f RUDER BO KOVI INSTITUTE   (Croatia)

^g UNIVERSITY OF GRAZ   (Austria)

Author keywords

4 hydroxynonenal; Adipogenesis; Insulin; Insulin resistance; Metformin; Obesity; Omental fat; T2DM

Indexed keywords

4 HYDROXYNONENAL; HEMOGLOBIN A1C; INSULIN; METFORMIN; 4-HYDROXY-2-NONENAL; ALDEHYDE;

ADIPOGENESIS; ADIPOSE TISSUE; ADULT; ARTICLE; BIOACCUMULATION; CCND1 GENE; CELL PROLIFERATION; CELL SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC OBESITY; DOWN REGULATION; FABP4 GENE; FEMALE; GENE; GENE EXPRESSION PROFILING; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; MACROPHAGE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OMENTAL ADIPOSE TISSUE; TSC22D3 GENE; UPREGULATION; ADIPOCYTE; BARIATRIC SURGERY; CELL CULTURE; COMBINATION DRUG THERAPY; CYTOLOGY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; OBESITY;

ADIPOCYTES; ADIPOGENESIS; ADULT; ALDEHYDES; BARIATRIC SURGERY; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INSULIN; MALE; METFORMIN; MIDDLE AGED; OBESITY;

EID: 85015643819     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2017.03.012     Document Type: Article

References (53)

1. [1] Kahn, S.E., Hull, R.L., Utzschneider, K.M., Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:7121 (2006), 840–846, 10.1038/nature05482.
2. [2] Bogardus, C., Lillioja, S., Mott, D.M., Hollenbeck, C., Reaven, G., Relationship between degree of obesity and in vivo insulin action in man. Am. J. Physiol. 248:3 Pt 1 (1985), E286–E291.
3. [3] Rutkowski, J.M., Stern, J.H., Scherer, P.E., The cell biology of fat expansion. J. Cell Biol. 208:5 (2015), 501–512, 10.1083/jcb.201409063.
4. [4] Cawthorn, W.P., Scheller, E.L., MacDougald, O.A., Adipose tissue stem cells meet preadipocyte commitment: going back to the future. J. Lipid Res. 53:2 (2012), 227–246, 10.1194/jlr.R021089.
5. [5] Almuraikhy, S., Kafienah, W., Bashah, M., Diboun, I., Jaganjac, M., Al-Khelaifi, F., et al. Interleukin-6 induces impairment in human subcutaneous adipogenesis in obesity-associated insulin resistance. Diabetologia 59:11 (2016), 2406–2416, 10.1007/s00125-016-4031-3.
6. [6] Elrayess, M.A., Al-Muraikhy, S., Kafienah, W., Al-Menhali, A., Al-Khalaifi, F., Bashah, M., et al. 4-hydroxynonenal causes impairment of human subcutaneous adipogenesis and induction of adipocyte insulin resistance. Free Radic. Biol. Med. 104 (2017), 129–137, 10.1016/j.freeradbiomed.2017.01.015 (Epub 2017 Jan 12).
7. [7] Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Investig. 114:12 (2004), 1752–1761, 10.1172/JCI21625.
8. [8] Higdon, A., Diers, A.R., Oh, J.Y., Landar, A., Darley-Usmar, V.M., Cell signalling by reactive lipid species: new concepts and molecular mechanisms. Biochem. J. 442:3 (2012), 453–464, 10.1042/BJ20111752.
9. [9] Jaganjac, M., Tirosh, O., Cohen, G., Sasson, S., Zarkovic, N., Reactive aldehydes – second messengers of free radicals in diabetes mellitus. Free Radic. Res. 47:Suppl. 1 (2013), S39–S48, 10.3109/10715762.2013.789136.
10. [10] Vazdar, M., Jurkiewicz, P., Hof, M., Jungwirth, P., Cwiklik, L., Behavior of 4-hydroxynonenal in phospholipid membranes. J. Phys. Chem. B 116:22 (2012), 6411–6415, 10.1021/jp3044219.
11. [11] Zarkovic, N., Cipak, A., Jaganjac, M., Borovic, S., Zarkovic, K., Pathophysiological relevance of aldehydic protein modifications. J. Proteom. 92 (2013), 239–247, 10.1016/j.jprot.2013.02.004.
12. [12] Grimsrud, P.A., Picklo, M.J. Sr., Griffin, T.J., Bernlohr, D.A., Carbonylation of adipose proteins in obesity and insulin resistance: identification of adipocyte fatty acid-binding protein as a cellular target of 4-hydroxynonenal. Mol. Cell. Proteom. 6:4 (2007), 624–637, 10.1074/mcp.M600120-MCP200.
13. [13] Dasuri, K., Ebenezer, P., Fernandez-Kim, S.O., Zhang, L., Gao, Z., Bruce-Keller, A.J., et al. Role of physiological levels of 4-hydroxynonenal on adipocyte biology: implications for obesity and metabolic syndrome. Free Radic. Res. 47:1 (2013), 8–19, 10.3109/10715762.2012.733003.
14. [14] Mattson, M.P., Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegenerative disorders. Exp. Gerontol. 44:10 (2009), 625–633, 10.1016/j.exger.2009.07.003.
15. [15] Weber, D., Milkovic, L., Bennett, S.J., Griffiths, H.R., Zarkovic, N., Grune, T., Measurement of HNE-protein adducts in human plasma and serum by ELISA-Comparison of two primary antibodies. Redox Biol. 1 (2013), 226–233, 10.1016/j.redox.2013.01.012.
16. [16] Bailey, C.J., Turner, R.C., Metformin. N. Engl. J. Med. 334:9 (1996), 574–579, 10.1056/NEJM199602293340906.
17. [17] Kirpichnikov, D., McFarlane, S.I., Sowers, J.R., Metformin: an update. Ann. Intern. Med. 137:1 (2002), 25–33.
18. [18] Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Hamman, R.F., Lachin, J.M., Walker, E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346:6 (2002), 393–403, 10.1056/NEJMoa012512.
19. [19] Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., Gerich, J.E., Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 333:9 (1995), 550–554, 10.1056/NEJM199508313330903.
20. [20] Lenhard, J.M., Kliewer, S.A., Paulik, M.A., Plunket, K.D., Lehmann, J.M., Weiel, J.E., Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways. Biochem. Pharmacol. 54:7 (1997), 801–808.
21. [21] Huypens, P., Quartier, E., Pipeleers, D., Van de Casteele, M., Metformin reduces adiponectin protein expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase. Eur. J. Pharmacol. 518:2–3 (2005), 90–95, 10.1016/j.ejphar.2005.06.016.
22. [22] Alexandre, K.B., Smit, A.M., Gray, I.P., Crowther, N.J., Metformin inhibits intracellular lipid accumulation in the murine pre-adipocyte cell line, 3T3-L1. Diabetes Obes. Metab. 10:8 (2008), 688–690, 10.1111/j.1463-1326.2008.00890.x.
23. [23] Wulffele, M.G., Kooy, A., Lehert, P., Bets, D., Ogterop, J.C., Borger van der Burg, B., et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 25:12 (2002), 2133–2140.
24. [24] Scarlett, J.A., Kolterman, O.G., Ciaraldi, T.P., Kao, M., Olefsky, J.M., Insulin treatment reverses the postreceptor defect in adipocyte 3-O-methylglucose transport in type II diabetes mellitus. J. Clin. Endocrinol. Metab. 56:6 (1983), 1195–1201, 10.1210/jcem-56-6-1195.
25. [25] Goyal, R., Faizy, A.F., Siddiqui, S.S., Singhai, M., Evaluation of TNF-alpha and IL-6 levels in obese and non-obese diabetics: pre- and postinsulin effects. N. Am. J. Med. Sci. 4:4 (2012), 180–184, 10.4103/1947-2714.94944.
26. [26] Klemm, D.J., Leitner, J.W., Watson, P., Nesterova, A., Reusch, J.E., Goalstone, M.L., et al. Insulin-induced adipocyte differentiation. Activation of CREB rescues adipogenesis from the arrest caused by inhibition of prenylation. J. Biol. Chem. 276:30 (2001), 28430–28435, 10.1074/jbc.M103382200.
27. [27] Sakaue, H., Ogawa, W., Matsumoto, M., Kuroda, S., Takata, M., Sugimoto, T., et al. Posttranscriptional control of adipocyte differentiation through activation of phosphoinositide 3-kinase. J. Biol. Chem. 273:44 (1998), 28945–28952.
28. [28] Gesta, S., Tseng, Y.H., Kahn, C.R., Developmental origin of fat: tracking obesity to its source. Cell 131:2 (2007), 242–256, 10.1016/j.cell.2007.10.004.
29. [29] Fischer, M., Timper, K., Radimerski, T., Dembinski, K., Frey, D.M., Zulewski, H., et al. Metformin induces glucose uptake in human preadipocyte-derived adipocytes from various fat depots. Diabetes, Obes. Metab. 12:4 (2010), 356–359, 10.1111/j.1463-1326.2009.01169.x.
30. [30] Grundy, S.M., Brewer, H.B. Jr., Cleeman, J.I., Smith, S.C. Jr., Lenfant, C., American Heart A, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:3 (2004), 433–438, 10.1161/01.CIR.0000111245.75752.C6.
31. [31] Bunnell, B.A., Estes, B.T., Guilak, F., Gimble, J.M., Differentiation of adipose stem cells. Methods Mol. Biol. 456 (2008), 155–171, 10.1007/978-1-59745-245-8_12.
32. [32] Lee, M.J., Wu, Y., Fried, S.K., A modified protocol to maximize differentiation of human preadipocytes and improve metabolic phenotypes. Obesity 20:12 (2012), 2334–2340, 10.1038/oby.2012.116.
33. [33] Poljak-Blazi, M., Jaganjac, M., Sabol, I., Mihaljevic, B., Matovina, M., Grce, M., Effect of ferric ions on reactive oxygen species formation, cervical cancer cell lines growth and E6/E7 oncogene expression. Toxicol. In Vitro: Int. J. 25:1 (2011), 160–166, 10.1016/j.tiv.2010.10.013.
34. [34] Jaganjac, M., Poljak-Blazi, M., Schaur, R.J., Zarkovic, K., Borovic, S., Cipak, A., et al. Elevated neutrophil elastase and acrolein-protein adducts are associated with W256 regression. Clin. Exp. Immunol. 170:2 (2012), 178–185, 10.1111/j.1365-2249.2012.04639.x.
35. [35] Spickett, C.M., Wiswedel, I., Siems, W., Zarkovic, K., Zarkovic, N., Advances in methods for the determination of biologically relevant lipid peroxidation products. Free Radic. Res. 44:10 (2010), 1172–1202, 10.3109/10715762.2010.498476.
36. [36] Frayn, K.N., Visceral fat and insulin resistance–causative or correlative*. Br. J. Nutr. 83:Suppl. 1 (2000), S71–S77.
37. [37] Miyatake, N., Takenami, S., Fujii, M., Evaluation of visceral adipose accumulation in Japanese women and establishment of a predictive formula. Acta Diabetol. 41:3 (2004), 113–117.
38. [38] Catalano, K.J., Stefanovski, D., Bergman, R.N., Critical role of the mesenteric depot versus other intra-abdominal adipose depots in the development of insulin resistance in young rats. Diabetes 59:6 (2010), 1416–1423, 10.2337/db08-0675.
39. [39] Fu, M., Rao, M., Bouras, T., Wang, C., Wu, K., Zhang, X., et al. Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment. J. Biol. Chem. 280:17 (2005), 16934–16941, 10.1074/jbc.M500403200.
40. [40] Garin-Shkolnik, T., Rudich, A., Hotamisligil, G.S., Rubinstein, M., FABP4 attenuates PPARgamma and adipogenesis and is inversely correlated with PPARgamma in adipose tissues. Diabetes 63:3 (2014), 900–911, 10.2337/db13-0436.
41. [41] Shi, X., Shi, W., Li, Q., Song, B., Wan, M., Bai, S., et al. A glucocorticoid-induced leucine-zipper protein, GILZ, inhibits adipogenesis of mesenchymal cells. EMBO Rep. 4:4 (2003), 374–380, 10.1038/sj.embor.embor805.
42. [42] Deng, T., Sieglaff, D.H., Zhang, A., Lyon, C.J., Ayers, S.D., Cvoro, A., et al. A peroxisome proliferator-activated receptor gamma (PPARgamma)/PPARgamma coactivator 1beta autoregulatory loop in adipocyte mitochondrial function. J. Biol. Chem. 286:35 (2011), 30723–30731, 10.1074/jbc.M111.251926.
43. [43] Han, C.Y., Roles of reactive oxygen species on insulin resistance in adipose tissue. Diabetes Metab. J. 40:4 (2016), 272–279, 10.4093/dmj.2016.40.4.272.
44. [44] Fang, L., Guo, F., Zhou, L., Stahl, R., Grams, J., The cell size and distribution of adipocytes from subcutaneous and visceral fat is associated with type 2 diabetes mellitus in humans. Adipocyte 4:4 (2015), 273–279, 10.1080/21623945.2015.1034920.
45. [45] Zarkovic, N., Schaur, R.J., Puhl, H., Jurin, M., Esterbauer, H., Mutual dependence of growth modifying effects of 4-hydroxynonenal and fetal calf serum in vitro. Free Radic. Biol. Med. 16:6 (1994), 877–884.
46. [46] Cipak, A., Jaganjac, M., Tehlivets, O., Kohlwein, S.D., Zarkovic, N., Adaptation to oxidative stress induced by polyunsaturated fatty acids in yeast. Biochim. Biophys. Acta 1781:6–7 (2008), 283–287, 10.1016/j.bbalip.2008.03.010.
47. [47] Sunjic, S.B., Cipak, A., Rabuzin, F., Wildburger, R., Zarkovic, N., The influence of 4-hydroxy-2-nonenal on proliferation, differentiation and apoptosis of human osteosarcoma cells. BioFactors 24:1–4 (2005), 141–148.
48. [48] Kreuzer, T., Zarkovic, N., Grube, R., Schaur, R.J., Inhibition of HeLa cell proliferation by 4-hydroxynonenal is associated with enhanced expression of the c-fos oncogene. Cancer Biotherapy Radiopharm. 12:2 (1997), 131–136, 10.1089/cbr.1997.12.131.
49. [49] Irons, B.K., Minze, M.G., Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated. Diabetes Metab. Syndr. Obes.: Targets Ther. 7 (2014), 15–24, 10.2147/DMSO.S38753.
50. [50] Anedda, A., Rial, E., Gonzalez-Barroso, M.M., Metformin induces oxidative stress in white adipocytes and raises uncoupling protein 2 levels. J. Endocrinol. 199:1 (2008), 33–40, 10.1677/JOE-08-0278.
51. [51] Dandona, P., Chaudhuri, A., Mohanty, P., Ghanim, H., Anti-inflammatory effects of insulin. Curr. Opin. Clin. Nutr. Metab. Care 10:4 (2007), 511–517, 10.1097/MCO.0b013e3281e38774.
52. [52] Luczaj, W., Gindzienska-Sieskiewicz, E., Jarocka-Karpowicz, I., Andrisic, L., Sierakowski, S., Zarkovic, N., et al. The onset of lipid peroxidation in rheumatoid arthritis: consequences and monitoring. Free Radic. Res. 50:3 (2016), 304–313, 10.3109/10715762.2015.1112901.
53. [53] Frijhoff, J., Winyard, P.G., Zarkovic, N., Davies, S.S., Stocker, R., Cheng, D., et al. Clinical relevance of biomarkers of oxidative stress. Antioxid. Redox Signal. 23:14 (2015), 1144–1170, 10.1089/ars.2015.6317.